Associated Papers
Correlation between p53 immunoexpression and TP53 mutation status in extrapulmonary small cell neuroendocrine carcinomas and its association with patient survival.
Pavlíčková K et al.
Virchows Archiv : an International Journal of Pathology, 2025
39843568 (PubMed )
Supplement: 428_2025_4024_MOESM1_ESM.xlsx › List1
Comprehensive characterization of early-onset lung cancer, in Chinese young adults.
Tian Y et al.
Nature Communications, 2025
40000630 (PubMed )
Supplement: 41467_2025_57309_MOESM8_ESM.xlsx › DNA_results
Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104).
Zhang C et al.
Cell Reports. Medicine, 2024
38897205 (PubMed )
Supplement: mmc10.xlsx › Sheet1
Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel associations between genomic alterations, TMB, and PD-L1.
Wallen ZD et al.
Frontiers in Oncology, 2024
39664186 (PubMed )
Supplement: Table2.xlsx › Supplementary_Table_2
TP53 germline pathogenic variants in modern humans were likely originated during recent human history.
Kou SH et al.
Nar Cancer, 2023
37304756 (PubMed )
Supplement: zcad025_supplemental_files.zip › Supplementary_Table_2.xlsx › PVs
Clinical significance of genetic profiling based on different anatomic sites in patients with mucosal melanoma who received or did not receive immune checkpoint inhibitors.
Wang HY et al.
Cancer Cell International, 2023
37649078 (PubMed )
Supplement: 12935_2023_3032_MOESM2_ESM.pdf
TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms.
Shah MV et al.
Blood Cancer Journal, 2023
Actionable Molecular Alterations Are Revealed in Majority of Advanced Non-Small Cell Lung Cancer Patients by Genomic Tumor Profiling at Progression after First Line Treatment.
Frank MS et al.
Cancers, 2021
35008297 (PubMed )
Supplement: cancers-14-00132-s001.zip › Supplementary_Table_S1.xlsx › Overview_ver2
Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors.
Cobain EF et al.
Jama Oncology, 2021
33630025 (PubMed )
Supplement: jamaoncol-e207987-s004.xlsx › Table
A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from the CONKO-005 trial.
Hoyer K et al.
Ebiomedicine, 2021
33862582 (PubMed )
Supplement: mmc3.xlsx › S5
Whole-exome mutational landscape of neuroendocrine carcinomas of the gallbladder.
Liu F et al.
Signal Transduction and Targeted Therapy, 2021
33563892 (PubMed )
Supplement: 41392_2020_412_MOESM17_ESM.xlsx › Supplementary_Table_S16
Identification of relevant genetic alterations in cancer using topological data analysis.
Rabadán R et al.
Nature Communications, 2020
32732999 (PubMed )
Supplement: 41467_2020_17659_MOESM3_ESM.xls › TableS1
Urothelial-to-Neural Plasticity Drives Progression to Small Cell Bladder Cancer.
Yang G et al.
Iscience, 2020
Genomic and Epigenomic Features of Primary and Recurrent Hepatocellular Carcinomas.
Ding X et al.
Gastroenterology, 2019
Interrogating Mutant Allele Expression via Customized Reference Genomes to Define Influential Cancer Mutations.
Grant AD et al.
Scientific Reports, 2019
31484939 (PubMed )
Supplement: 41598_2019_48967_MOESM2_ESM.xls › Supplementary_Variant_File
Design and MinION testing of a nanopore targeted gene sequencing panel for chronic lymphocytic leukemia.
Orsini P et al.
Scientific Reports, 2018
30087429 (PubMed )
Supplement: 41598_2018_30330_MOESM3_ESM.xlsx › recurrent_mutations
Genetic alterations of triple negative breast cancer by targeted next-generation sequencing and correlation with tumor morphology.
Weisman PS et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2016
26939876 (PubMed )
Supplement: NIHMS752475-supplement-3.xlsx › Supplementary_Table_3
Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions.
Brannon AR et al.
Genome Biology, 2014
25164765 (PubMed )
Supplement: 13059_2014_454_MOESM1_ESM.xlsx › Sheet1
Select a paper to view details